Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The role of adipokines in the rapid antidepressant effects of ketamine
Rodrigo Machado‐Vieira, Philip W. Gold, David A. Luckenbaugh, et al.
Molecular Psychiatry (2016) Vol. 22, Iss. 1, pp. 127-133
Open Access | Times Cited: 89

Showing 1-25 of 89 citing articles:

Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders
Ebrahim Haroon, Andrew H. Miller, Gerard Sanacora
Neuropsychopharmacology (2016) Vol. 42, Iss. 1, pp. 193-215
Open Access | Times Cited: 445
Prognosis and improved outcomes in major depression: a review
Christoph Kraus, Bashkim Kadriu, Rupert Lanzenberger, et al.
Translational Psychiatry (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 384
Bipolar Disorder and Immune Dysfunction: Epidemiological Findings, Proposed Pathophysiology and Clinical Implications
Joshua D. Rosenblat, Roger S. McIntyre
Brain Sciences (2017) Vol. 7, Iss. 11, pp. 144-144
Open Access | Times Cited: 222
Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers
Dmitriy Matveychuk, Rejish K. Thomas, Jennifer Swainson, et al.
Therapeutic Advances in Psychopharmacology (2020) Vol. 10
Open Access | Times Cited: 164
Peripheral Markers of Depression
Aleksander Nobis, Daniel Zalewski, Napoleon Waszkiewicz
Journal of Clinical Medicine (2020) Vol. 9, Iss. 12, pp. 3793-3793
Open Access | Times Cited: 141
Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome
Drew D. Kiraly, Sarah R. Horn, Nicholas T. Van Dam, et al.
Translational Psychiatry (2017) Vol. 7, Iss. 3, pp. e1065-e1065
Open Access | Times Cited: 158
Role of Adiposity-Driven Inflammation in Depressive Morbidity
Lucile Capuron, Julie Lasselin, Nathalie Castanon
Neuropsychopharmacology (2016) Vol. 42, Iss. 1, pp. 115-128
Open Access | Times Cited: 151
Inflammation Effects on Brain Glutamate in Depression: Mechanistic Considerations and Treatment Implications
Ebrahim Haroon, Andrew H. Miller
Current topics in behavioral neurosciences (2016), pp. 173-198
Closed Access | Times Cited: 129
Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic
John H. Krystal, Chadi G. Abdallah, Lynette A. Averill, et al.
Current Psychiatry Reports (2017) Vol. 19, Iss. 10
Open Access | Times Cited: 114
Ketamine as a rapid-acting agent for suicidal ideation: A meta-analysis
Francesco Bartoli, Ilaria Riboldi, Cristina Crocamo, et al.
Neuroscience & Biobehavioral Reviews (2017) Vol. 77, pp. 232-236
Closed Access | Times Cited: 104
Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder
Carola Rong, Caroline Park, Joshua D. Rosenblat, et al.
International Journal of Environmental Research and Public Health (2018) Vol. 15, Iss. 4, pp. 771-771
Open Access | Times Cited: 97
Inflammatory signaling mechanisms in bipolar disorder
Gregory Jones, Courtney M. Vecera, Omar F. Pinjari, et al.
Journal of Biomedical Science (2021) Vol. 28, Iss. 1
Open Access | Times Cited: 84
The kynurenine pathway and bipolar disorder: intersection of the monoaminergic and glutamatergic systems and immune response
Bashkim Kadriu, Cristan Farmer, Peixiong Yuan, et al.
Molecular Psychiatry (2019) Vol. 26, Iss. 8, pp. 4085-4095
Open Access | Times Cited: 78
Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis
Gustavo C. Medeiros, Todd D. Gould, William L. Prueitt, et al.
Molecular Psychiatry (2022) Vol. 27, Iss. 9, pp. 3658-3669
Open Access | Times Cited: 39
Inflammation, stress and depression: An exploration of ketamine’s therapeutic profile
Jenessa N. Johnston, Maximillian Greenwald, Ioline D. Henter, et al.
Drug Discovery Today (2023) Vol. 28, Iss. 4, pp. 103518-103518
Open Access | Times Cited: 36
A Phase II, Open-Label Clinical Trial of Intranasal Ketamine for Depression in Patients with Cancer Receiving Palliative Care (INKeD-PC Study)
Joshua D. Rosenblat, Froukje E. deVries, Zoe Doyle, et al.
Cancers (2023) Vol. 15, Iss. 2, pp. 400-400
Open Access | Times Cited: 32
Effect of esketamine on postpartum depression after labor analgesia and potential mechanisms: a randomized, double-blinded controlled trial
Wei Wang, Bin Ling, Haibo Zhao, et al.
BMC Anesthesiology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 8
Mitochondrial Metabolism in Major Depressive Disorder: From Early Diagnosis to Emerging Treatment Options
Ane Larrea, Laura Sánchez-Sánchez, Eguzkiñe Díez-Martín, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 6, pp. 1727-1727
Open Access | Times Cited: 8
Ketamine’s mechanism of action with an emphasis on neuroimmune regulation: can the complement system complement ketamine’s antidepressant effects?
Brandi Quintanilla, Carlos A. Zarate, Anilkumar Pillai
Molecular Psychiatry (2024) Vol. 29, Iss. 9, pp. 2849-2858
Closed Access | Times Cited: 8
Crosstalk Between Inflammation and Glutamate System in Depression: Signaling Pathway and Molecular Biomarkers for Ketamine’s Antidepressant Effect
Wenyan Cui, Yuping Ning, Wu Hong, et al.
Molecular Neurobiology (2018) Vol. 56, Iss. 5, pp. 3484-3500
Closed Access | Times Cited: 81
Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression
Minkyung Park, Laura Newman, Philip W. Gold, et al.
Journal of Psychiatric Research (2016) Vol. 84, pp. 113-118
Open Access | Times Cited: 80
Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness
Rejish K. Thomas, Glen B. Baker, J. Lind, et al.
Journal of Psychopharmacology (2018) Vol. 32, Iss. 10, pp. 1110-1117
Closed Access | Times Cited: 62
Alterations of multiple peripheral inflammatory cytokine levels after repeated ketamine infusions in major depressive disorder
Yanni Zhan, Yanling Zhou, Wei Zheng, et al.
Translational Psychiatry (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 60
Prognosis and Improved Outcomes in Major Depression: A Review
Christoph Kraus, Bashkim Kadriu, Rupert Lanzenberger, et al.
FOCUS The Journal of Lifelong Learning in Psychiatry (2020) Vol. 18, Iss. 2, pp. 220-235
Open Access | Times Cited: 57
Targeting inflammation in depression: Ketamine as an anti-inflammatory antidepressant in psychiatric emergency
Naghmeh Nikkheslat
Brain Behavior & Immunity - Health (2021) Vol. 18, pp. 100383-100383
Open Access | Times Cited: 41
Page 1 - Next Page

Scroll to top